Financial

Bayer Signs Letter of Intent to Build New Distribution Center in Saxonburg, PA

New 220,000 square-foot Distribution Center to support ongoing growth of business PITTSBURGH–(BUSINESS WIRE)–Bayer announced its plans to build a new 220,000 sq. ft. Distribution Center to support the ongoing growth of Bayer’s Radiology global business that supplies medical device products world-wide. A 10-year lease with optional extensions is being negotiated. […]

Corventive Health Partners with Halfpenny Technologies to Enhance its Cardiac Care Solutions

NEWTOWN, Pa., Oct. 26, 2020 /PRNewswire/ — Corventive Health, a provider of cloud-based and AI technology solutions, announced a partnership with Halfpenny Technologies, an Accumen, Inc. company today. This partnership fortifies Corventive’s core capability of delivering clinical insights that improve care coordination and cardiac outcomes. Corventive provides early cardiovascular disease detection and intervention […]

Titan Medical Announces Achievement of $10 Million Technical Milestone Under Medtronic Development and License Agreement

TORONTO–(BUSINESS WIRE)–Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed the first technical milestone under the development and license agreement with Medtronic plc (“Medtronic”) […]

Zynex Appoints Neil Friery as President and Chief Operating Officer of Monitoring Solutions Division

ENGLEWOOD, Colo., Oct. 23, 2020 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has hired Neil Friery as the President and Chief Operating Officer (COO) of its Monitoring Solutions Division. As […]

Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants

MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the pricing of its previously announced underwritten public offering of 3,810,097 of its common shares, and to certain investors in lieu […]

BD Announces Executive Leadership Appointments

Patrick Kaltenbach appointed chief technology officer Dave Hickey promoted to president, Life Sciences segment FRANKLIN LAKES, N.J., Oct. 22, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology officer, and the promotion of Dave Hickey to executive vice […]

Sequana Medical Announces Strong Interim Results From RED DESERT alfapump® DSR Study and Provides Business Update

RED DESERT: Results from first five patients indicaterepeated dose alfapump DSR therapy to be safeandeffective Interim data support DSR hypothesis: kidneys eliminate free water to maintain patients’ serum sodium levels No patients required loop diuretic therapy during the six-week alfapump DSR treatment period Followingalfapump DSR treatment, loop diuretic responsiveness was restored to near normal levels; effect was durable for months post-treatmentwith majority of patients requiring little or no diuretic therapy Full RED DESERT data on track […]

Edwards Lifesciences Reports Third Quarter Results

IRVINE, Calif., Oct. 21, 2020 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2020. Third Quarter Highlights and Outlook Sales of $1.1 billion grew 4%; similar underlying1 growth expected in the fourth quarter TAVR global sales grew 6% EPS was $0.52; adjusted1 EPS grew 9% to $0.51 TMTT clinical trials now enrolling […]

InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing

Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for Presentation at American Heart Association Scientific Sessions 2020; Pivotal Phase 3 Study Planned for Initiation in H1 2021 SAN FRANCISCO, Oct. 21, 2020 (GLOBE NEWSWIRE) —  InCarda Therapeutics, […]